Skip to content

Comparison of Intravenous Ibuprofen versus Intravenous Paracetamol for Postoperative Pain Management in Vaginal Hysterectomy Patients Under Spinal Anaesthesia.

A prospective randomized study to compare Intravenous Ibuprofen versus Intravenous Paracetamol in post operative pain management of vaginal hysterectomy patients under spinal anesthesia. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/10/095897
Enrollment
40
Registered
2025-10-10
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Drug: Intravenous Ibuprofen Drug: Intravenous Paracetamol: Intervention 1 (Group I): Intravenous Ibuprofen 800mg , 8 hourly Intervention 2 (Group P): Intravenous Paracetamol 1g, 8 hour

Sponsors

GMERS Medical College and Hospital Gotri Vadodara
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Female patient posted for Vaginal hysterectomy under Spinal anesthesia consenting for participating in this study Patient aged between 35-65 years All elective surgeries of ASA I and II patients

Exclusion criteria

Exclusion criteria: 1.Patient s refusal 2.History of allergy or hypersensitivity to NSAIDs 3.History of Peptic ulcer or intestinal Inflammatory disease. 4.Contraindications for spinal anaesthesia 5.Coagulation disorders 6.Any systemic organ involvement or any other co morbidity. 7.Duration of Surgery more than 2 hours

Design outcomes

Primary

MeasureTime frame
Total opioid consumption in 24 hours with use of two study drugsTimepoint: Total opioid consumption in 24 hours with use of two study drugs

Secondary

MeasureTime frame
To Compare the duration of analgesia with either of the study drug (from first administration to requirement of rescue analgesia) To assess hemodynamic stability of both drugs To compare incidence of adverse eventsTimepoint: Immediate postoperatively, a baseline VAS observed Study drug administered 30 mins after shifting the patient to a recovery room VAS Score assessed at 30 min,60 min, 90min, 2hrs & there after every 2 hrs following the 1st dose till 24 hours

Countries

India

Contacts

Public ContactDr. Pooja Zala

GMERS Medical college and Hospital, Gotri, Vadodara

anupchandnani29@gmail.com9925436505

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026